Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 149 Breast Neoplasms 38 Prostatic Neoplasms 31 Insulin Resistance 30 Obesity 23 Endometrial Neoplasms 15 Neoplasms 14 Infertility 14 Colorectal Neoplasms 13 Pancreatic Neoplasms 12 Carcinoma, Non-Small-Cell Lung 12 Anovulation 10 Lung Neoplasms 9 Neoplasm Metastasis 8 Hyperandrogenism 8 Glioblastoma 8 Diabetes Mellitus 8 Squamous Cell Carcinoma of Head and Neck 7 Metabolic Syndrome 7 Melanoma 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Ovarian Neoplasms 5 Lymphoma, Large B-Cell, Diffuse 5 Head and Neck Neoplasms 5 Brain Neoplasms 5 Adenocarcinoma 5 Weight Loss 4 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Rectal Neoplasms 4

Interventions

Trastuzumab 30 pertuzumab 16 Docetaxel 16 pyrotinib 11 Paclitaxel 7 Carboplatin 5 Capecitabine 5 Ado-Trastuzumab Emtansine 4 tucatinib 3 trastuzumab deruxtecan 2 atezolizumab 2 Protons 2 Neoadjuvant Therapy 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 neratinib 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Fluorodeoxyglucose F18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-positive Breast Cancer × Metformin × Clear all

NCT03238495 2021-12-07

HERMET

University of Kansas Medical Center

Phase 2 Unknown

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡